BioCryst to Host Virtual R&D Day on March 22, 2021
March 15 2021 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company will host a virtual R&D day on Monday, March 22,
2021 from 9:00 am to 11:00 am ET.
The program will cover BioCryst’s unique, proven
and prolific approach to developing oral medicines for rare
diseases, with a focus on BCX9930, an oral Factor D inhibitor being
developed as a monotherapy for the treatment of complement-mediated
diseases.
BioCryst plans to present new data from a
dose-ranging clinical trial of BCX9930 that enrolled 16 paroxysmal
nocturnal hemoglobinuria (PNH) patients (10 treatment-naïve PNH
patients with no prior treatment with C5 inhibitors and six PNH
patients with an inadequate response to C5 inhibitors).
The event will feature presentations from the
BioCryst management team, and a panel discussion with a PNH patient
and physician key opinion leaders.
The live video webcast and replay of the event
may be accessed at:
https://onlinexperiences.com/Launch/QReg/ShowUUID=0108DF33-EA47-4C52-B45E-A49134DC75CF or
in the Investors section of BioCryst’s website at
http://www.biocryst.com.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States and Japan
for the prevention of HAE attacks in adults and pediatric patients
12 years and older, and under regulatory review for approval in the
European Union and United Kingdom. BioCryst has several ongoing
development programs including BCX9930, an oral Factor D inhibitor
for the treatment of complement-mediated diseases, BCX9250, an
ALK-2 inhibitor for the treatment of fibrodysplasia ossificans
progressiva, and galidesivir, a potential treatment for Marburg
virus disease and Yellow Fever. RAPIVAB® (peramivir
injection), a viral neuraminidase inhibitor for the treatment of
influenza, has received regulatory approval in the U.S., Canada,
Australia, Japan, Taiwan and Korea. Post-marketing commitments for
RAPIVAB are ongoing. For more information, please visit the
company’s website at www.biocryst.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements regarding the development of oral
medicines. These statements involve known and unknown risks,
uncertainties and other factors which may cause BioCryst’s actual
results, performance, or achievements to be materially different
from those expressed or implied by the forward-looking statements.
These statements reflect our current views with respect to future
events and are based on assumptions and are subject to risks and
uncertainties. Given these uncertainties, you should not place
undue reliance on these forward-looking statements. Some of the
factors that could affect the forward-looking statements contained
herein include: ongoing and future preclinical and clinical
development of BCX9930 may not have positive results; BioCryst may
not be able to enroll the required number of subjects in planned
clinical trials of product candidates; BioCryst may not advance
human clinical trials with product candidates as expected; the FDA
or other applicable regulatory agency may require additional
studies beyond the studies planned for product candidates, may not
provide regulatory clearances which may result in delay of planned
clinical trials, may impose certain restrictions, warnings, or
other requirements on product candidates, may impose a clinical
hold with respect to product candidates, or may withhold or delay
market approval for product candidates. Please refer to the
documents BioCryst files periodically with the Securities and
Exchange Commission, specifically BioCryst’s most recent Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current
Reports on Form 8-K, all of which identify important factors that
could cause the actual results to differ materially from those
contained in BioCryst’s projections and forward-looking
statements.
BCRXW
Contact:InvestorsJohn Bluth+1 919
859 7910jbluth@biocryst.com
MediaCatherine Collier
Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024